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Brief communications 
Effect of celite and kaolin on activated clotting 
time in the presence of aprotinin: Activated 
clotting time is reduced by binding of aprotinin 
to kaolin 
W. Dietrich, MD, and M. Jochum, PhD, 
Munich, Germany 
Prolongation of the activated clotting time (ACT) by 
celite is a widely known effect of high-dose aprotinin 
application in cardiac surgery. 1 In contrast, kaolin-acti- 
vated ACT is not influenced by aprotinin. 2 In a recent 
publication in this JOURNAL, Wang and associates 3 pecu- 
lated that celite may "artificially" prolong ACT, thus 
rendering the control f anticoagulation by the celite ACT 
unreliable. This may lead to underheparinization f the 
patient. 4 The possibility of insufficient anticoagulation was 
even blamed for an increase of the prevalence of myocar- 
dial ischemia or infarction during and after cardiac oper- 
ations, s 
To investigate the influence of either celite or kaolin on 
the ACT in the presence of aprotinin, we performed the 
following study. After obtaining informed consent, we 
took blood samples to determine the plasma aprotinin 
concentrations in 11 patients who were treated with 
high-dose aprotinin during cardiac operations (total dos- 
age 6 × 10 6 KIU). All patients received mucosa heparin in 
a dose of 375 U/kg for cardiopulmonary b pass (CPB). 
The samples consisted of 2 ml of citrate-treated blood 
rotated for 10 minutes in either celite or kaolin test tubes 
in an automated ACT device (Hemochron, International 
Technidyne Corp, Edison, N.J.). Thereafter the celite- 
and kaolin-activated blood samples and an additional 
sample, which was not in contact with an activator, were 
centrifuged at 3000 g for 10 minutes and the supernatant 
plasma was frozen immediately. In these plasma samples 
aprotinin concentrations were measured by a specific 
enzyme-linked immunosorbent assay test. 6 Measurements 
were performed either before or 30 minutes after the 
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onset of CPB. Data were compared with the paired 
Student's t test with the Bonferroni correction. 
Results are given in Fig. 1. Aprotinin concentrations in 
plasma from celite tubes were slightly lower than those in 
plasma without contact with an activator (134 _+ 49 versus 
88 + 39 KIU/ml, p < 0.05). In contrast, in the kaolin 
tubes, aprotinin was considerably diminished up to 6.7 --- 
4.6 KIU/ml (lower detection limit of the assay: 1 to 5 
KIU/ml). 
In the neutral pH range, aprotinin is a highly positively 
charged molecule, whereas kaolin is more negatively 
charged than celite. In our experiment, aprotinin was 
nearly undetectable in the plasma that was in contact with 
kaolin. These results suggest that the positively charged 
aprotinin is bound to kaolin in the test tube. Therefore, 
aprotinin cannot inhibit contact-phase activation that 
takes place during rotation in the test tube. 
As a result, there is no "artificial" prolongation of the 
celite ACT. The celite ACT is prolonged because of the 
inhibition of the contact-phase activation in the presence 
of aprotinin. In contrast, the kaolin ACT is "artificially" 
shortened because aprotinin is bound to kaolin in the test 
tube and, consequently, contact phase activation is not 
inhibited in these samples. Thus only celite ACT mirrors 
this contact-phase inhibition by aprotinin. The question 
remains, however, whether the inhibition of the contact 
phase, which occurs during CPB, s is of clinical relevance. 
On the basis of our previous results, 9we are convinced 
that inhibition of the contact-phase activation during CPB 
by aprotinin leads to a synergistic effect to heparin on 
anticoagulation a d, finally, to better preserved hemosta- 
sis during CPB. Therefore inhibition of contact-phase 
activation seems to be of clinical relevance. 
Until this question is finally answered, it seems advis- 
able to measure ACT during CPB with both celite and 
kaolin tubes. Because kaolin excludes the anticoagulatory 
effect of aprotinin, standard accepted heparin levels may 
be better monitored with the kaolin ACT. For safety 
reasons, heparinization (which is not synonymous with 
anticoagulation, especially in the presence of aprotinin) 
may be based on the kaolin time, though our experience 1°
suggests that the celite ACT is reliable and does not lead 
to underheparinization during cardiac operations. 
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Fig. 1. Aprotinin plasma concentrations. The left part of the figure shows aprotinin concentrations (mean + 
standard eviation) in plasma samples directly drawn from the patient and in specimens that were rotated for 
10 minutes in either celite or kaolin test tubes. The right side shows the individual measurements for each 
patient. Aprotinin was almost undetectable in the kaolin tubes, which indicates abinding of aprotinin to kaolin. 
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Use of an intraluminal shunt to repair a coronary 
bypass graft injury during resternotomy 
T. Carrel, MD, M. Pasic, MD, U. Niederhfiuser, 
MD, and M. Turina, MD, Zurich, Switzerland 
In recent years, there has been an increase in the 
number of patients who are subjected to second cardiac 
procedures for correction of congenital heart defects, 
valve problems, and repeat coronary artery revasculariza- 
tion. Catastrophic hemorrhage is a rare complication that 
may occur while the sternum is being reopened. The most 
frequent causes include tears of the right ventricle and 
lesions of previous coronary bypass grafts; less common 
are bleeding from ascending aortic aneurysms or tears in 
the right atrium. 
In 1985, a 66-year old patient had undergone an aortic 
valve replacement with a Capentier-Edwards bioprosthe- 
sis (Baxter Healthcare Corp., Edwards Div., Santa Aria, 
Calif.) and a saphenous vein graft to the circumflex artery 
with jump anastomoses to an intermediate branch, the 
first diagonal branch, and the left anterior descending 
artery. Postoperative r covery was uneventful, and the 
patient felt well until 1992. At this time, the patient 
reported having exertional dyspnea nd increasing weari- 
ness. A cardiologic examination was performed and trans- 
thoracic echocardiography demonstrated degeneration f
the bioprosthesis, resulting in moderate aortic stenosis 
(mean systolic gradient 45 mm Hg, peak-to-peak gradient 
70 mm Hg, and a valve opening area of 0.8 cm2). I~ft 
ventricular function was severely depressed with an ejec- 
tion fraction of 0.26. At coronary angiography, each 
coronary-saphenous vein anastomosis was patent but 
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